Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Advanced non-small cell lung cancer (NSCLC) management relies on identifying actionable mutations for targeted therapies and immunotherapy.
• Current diagnostic approaches involve comprehensive genetic profiling to guide treatment decisions.

Purpose of the Study:

• To evaluate the utility of reverse transcriptase polymerase chain reaction (RT-PCR) for diagnosing gene rearrangements.
• To assess the effectiveness of EGFR, ALK, ROS1, and PD-L1 inhibitors in first-line NSCLC treatment.
• To determine the role of predictive factor diagnosis in survival outcomes for advanced NSCLC patients.

Main Methods:

• Utilized real-time PCR, fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and RT-PCR.
• Analyzed data from 95 non-squamous NSCLC patients with known genetic status (EGFR, ALK, ROS1, MET, RET) and PD-L1 expression.

Main Results:

• Patients with ALK and ROS1 gene alterations receiving crizotinib showed a median overall survival of 34 months versus 6 months with chemotherapy (HR=0.266, p=0.0056).
• The risk of death was significantly lower in patients receiving targeted therapies or immunotherapy compared to those without personalized treatment or receiving chemotherapy.
• Diagnosis of predictive factors and subsequent personalized treatment implementation are crucial for survival prolongation.

Conclusions:

• RT-PCR is a valuable tool for diagnosing gene rearrangements in NSCLC.
• Personalized treatment strategies based on genetic profiling and predictive factors significantly improve survival in advanced NSCLC.
• Comprehensive molecular diagnostics are essential for optimizing first-line treatment and patient outcomes in NSCLC.